Stockreport

Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate

Valneva SE - American Depositary Shares  (VALN) 
PDF Saint Herblain (France), June 10, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophy [Read more]